GRAMD1B

Across TCGA pan-cancer cohorts, GRAMD1B mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of GRAMD1B’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where GRAMD1B mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types GRAMD1B is over-expressed in tumor, although a few such as CCRCC and LUAD show the opposite, repressed pattern.

PDAC, CCRCC, and LUAD are the cancer types where GRAMD1B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GRAMD1B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	All	All	+0.415	.004	4	view →
CCRCC	Male	All	−0.254	.028	3	view →
LUAD	All	III,IV	−0.827	.012	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

GRAMD1B–PDAC

Open the PDAC breakdown →